BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial ...

The chikungunya virus virus-like particle vaccine is well tolerated and shows high immunogenicity in both previous recipients ...

Six years before the start of the COVID-19 pandemic, an Ebola outbreak in West Africa had people fearing the possibility of a ...

In the Virus-Like Particle Translational Oncology Laboratory, Qizhi Cathy Yao, M.D., Ph.D. is developing non-infectious HIV virus-like particles (VLPs) as candidate HIV mucosal vaccines for both ...

Vimkunya is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older.

Valneva will work with local health authorities and wholesalers on the French island territory to distribute the vaccines.

Intech Investment Management LLC acquired a new stake in shares of HilleVax, Inc. (NASDAQ:HLVX – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with ...

The formation of VLP is depicted in Figure 1. Figure 1. The formation of a virus-like particle (VLP). Image Credit: Sino Biological Inc. To enable targeted drug research, Sino Biological has ...

The global animal vaccines market was valued at $9,093.9 million in 2020, and is projected to reach $13,780.6 million by 2028, registering a CAGR of 5.3% from 2021 to 2028. The market is expected to ...

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) have received an average recommendation of “Buy” from the seven ...